DE602004011076D1 - Piperazin mit or-substituierter phenylgruppe und deren verwendung als glyt1-inhibitoren - Google Patents

Piperazin mit or-substituierter phenylgruppe und deren verwendung als glyt1-inhibitoren

Info

Publication number
DE602004011076D1
DE602004011076D1 DE602004011076T DE602004011076T DE602004011076D1 DE 602004011076 D1 DE602004011076 D1 DE 602004011076D1 DE 602004011076 T DE602004011076 T DE 602004011076T DE 602004011076 T DE602004011076 T DE 602004011076T DE 602004011076 D1 DE602004011076 D1 DE 602004011076D1
Authority
DE
Germany
Prior art keywords
piperazine
phenyl group
substituted phenyl
glyt1 inhibitors
glyt1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004011076T
Other languages
English (en)
Other versions
DE602004011076T2 (de
Inventor
Synese Jolidon
Robert Narquizian
Matthias Heinrich Nettekoven
Roger David Norcross
Emmanuel Pinard
Henri Stalder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34130061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602004011076(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE602004011076D1 publication Critical patent/DE602004011076D1/de
Application granted granted Critical
Publication of DE602004011076T2 publication Critical patent/DE602004011076T2/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
DE602004011076T 2003-08-11 2004-08-02 Piperazin mit or-substituierter phenylgruppe und deren verwendung als glyt1-inhibitoren Active DE602004011076T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03017614 2003-08-11
EP03017614 2003-08-11
PCT/EP2004/008633 WO2005014563A1 (en) 2003-08-11 2004-08-02 Piperazine with or-substituted phenyl group and their use as glyt1 inhibitors

Publications (2)

Publication Number Publication Date
DE602004011076D1 true DE602004011076D1 (de) 2008-02-14
DE602004011076T2 DE602004011076T2 (de) 2009-01-02

Family

ID=34130061

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004011076T Active DE602004011076T2 (de) 2003-08-11 2004-08-02 Piperazin mit or-substituierter phenylgruppe und deren verwendung als glyt1-inhibitoren

Country Status (37)

Country Link
US (2) US7319099B2 (de)
EP (1) EP1656361B1 (de)
JP (1) JP4252598B2 (de)
KR (1) KR100774622B1 (de)
CN (1) CN1867554B (de)
AR (1) AR045360A1 (de)
AT (1) ATE382611T1 (de)
AU (1) AU2004263306B2 (de)
BR (1) BRPI0413497B8 (de)
CA (1) CA2534675C (de)
CO (1) CO5650253A2 (de)
CR (1) CR8193A (de)
CY (1) CY1108616T1 (de)
DE (1) DE602004011076T2 (de)
DK (1) DK1656361T3 (de)
EA (1) EA009986B1 (de)
EC (1) ECSP066358A (de)
EG (1) EG26404A (de)
ES (1) ES2297458T3 (de)
HK (1) HK1098147A1 (de)
HR (1) HRP20080137T3 (de)
IL (1) IL173274A (de)
MA (1) MA27995A1 (de)
ME (1) ME00116B (de)
MX (1) MXPA06001665A (de)
MY (1) MY145356A (de)
NO (1) NO332263B1 (de)
NZ (1) NZ544820A (de)
PL (1) PL1656361T3 (de)
PT (1) PT1656361E (de)
RS (2) RS20060076A (de)
SI (1) SI1656361T1 (de)
TN (1) TNSN06042A1 (de)
TW (1) TWI289556B (de)
UA (1) UA85194C2 (de)
WO (1) WO2005014563A1 (de)
ZA (1) ZA200601146B (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
ES2297458T3 (es) 2003-08-11 2008-05-01 F. Hoffmann-La Roche Ag Piperazina con grupo fenilo or-sustituido y su empleo como inhibidores de glyti.
DE602004009323T2 (de) * 2003-09-09 2008-07-10 F. Hoffmann-La Roche Ag 1-(2-amino-benzoyl)-piperazin-derivate als glycin-aufnahmehemmer zur behandlung von psychosen
RU2355683C2 (ru) * 2003-09-09 2009-05-20 Ф.Хоффманн-Ля Рош Аг Производные 1-бензоилпиперазина в качестве ингибиторов поглощения глицина для лечения психозов
EP2289510A1 (de) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterozyklische Derivate zur Behandlung von durch Stearoyl-Coa-Desaturase-Enzyme verursachten Krankheiten
MX2007003321A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
BRPI0515477A (pt) * 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos bicìclicos e o uso dos mesmos como inibidores de estaroil-coa-desaturase (scd)
WO2006034440A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP2316458A1 (de) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazin-Derivate zur Verhinderung menschlicher Stearoyl-coa-desaturas
CN101084207A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
US7592343B2 (en) * 2004-09-20 2009-09-22 Xenon Pharmaceuticals Inc. Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors
CN101084212A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途
US20080167321A1 (en) * 2004-09-20 2008-07-10 Xenon Pharmaceuticals Inc. Pyridine Derivatives For Inhibiting Human Stearoyl-Coa-Desaturase
PT1828154E (pt) * 2004-12-09 2009-06-08 Hoffmann La Roche Derivados de fenil-piperazina-metanona
ATE457989T1 (de) * 2004-12-15 2010-03-15 Hoffmann La Roche Bi- und trizyklische substituierte phenyl- methanone als inhibitoren von glycin-i (glyt-1)- transportern zur behandlung der alzheimer- krankheit
US7485637B2 (en) * 2005-01-04 2009-02-03 Hoffmann-La Roche Inc. Benzoyl-tetrahydropiperidine derivatives
RU2007125380A (ru) * 2005-01-06 2009-02-20 Ф. Хоффманн-Ля Рош Аг (Ch) Сульфанил-замещенные фенилметаноны в качестве ингибиторов переносчика глицина 1 (glyt-1) для лечения неврологических и психоневрологических заболеваний
DE602005022113D1 (de) 2005-01-07 2010-08-12 Hoffmann La Roche Phenyl)methanon-derivate als glycin-transporter 1 (glyt-1) hemmer zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
ATE435650T1 (de) * 2005-01-18 2009-07-15 Hoffmann La Roche 2,5-disubstituierte phenylmethanonderivative als glycintransporter-1-inhibitoren (glyt-1) zur behandlung von neurologischen und neuropsychiatrischen störungen
DE602006010175D1 (de) * 2005-01-26 2009-12-17 Hoffmann La Roche Phenylmethanonderivate und ihre verwendung als glycin-transporter-1-hemmer
ES2334578T3 (es) * 2005-02-07 2010-03-12 F. Hoffmann-La Roche Ag Fenil-metanonas sustituidas por heterociclo como inhibidores del transportador 1 de la glicina.
GB0505085D0 (en) * 2005-03-11 2005-04-20 Glaxo Group Ltd Compounds
GB0505084D0 (en) * 2005-03-11 2005-04-20 Glaxo Group Ltd Compounds
GB0505086D0 (en) * 2005-03-11 2005-04-20 Glaxo Group Ltd Compounds
CN101208089A (zh) 2005-06-03 2008-06-25 泽农医药公司 氨基噻唑衍生物作为人硬酯酰-CoA去饱和酶抑制剂
WO2007006650A2 (en) * 2005-07-08 2007-01-18 F. Hoffmann-La Roche Ag Asymmetric reduction of 1,1,1-trifluoroacetone
GB0523853D0 (en) * 2005-11-24 2006-01-04 3M Innovative Properties Co Fluorinated surfactants for use in making a fluoropolymer
EP1968961A2 (de) * 2005-12-21 2008-09-17 Decode Genetics EHF Heterocyclische, stickstoffhaltige biarylinhibitoren von lta4h zur behandlung von entzündungen
CA2651700A1 (en) * 2006-05-22 2007-11-29 Merck Frosst Canada Ltd. Cyclic amine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AU2007263083B2 (en) 2006-06-22 2012-10-04 F. Hoffmann-La Roche Ag Substituted phenyl methanone derivatives
EP2565183A1 (de) 2006-06-28 2013-03-06 Amgen Inc. Inhibitoren des Glycintransporters 1
AU2007278274B2 (en) 2006-07-27 2012-09-13 F. Hoffmann-La Roche Ag Asymmetric hydrogenation of 1,1,1-trifluoroacetone
KR101364353B1 (ko) * 2006-11-30 2014-02-18 다우 아그로사이언시즈 엘엘씨 2-치환된-5-(1-알킬티오)알킬피리딘의 제조 방법
SI2114405T1 (sl) * 2006-12-28 2015-06-30 F. Hoffmann-La Roche Ag Kokristalna oblika "a" metilparabena (4-(3-fluoro-5-trifluorometil-piridin-2-il)-piperazin-1-il)-(5-metan- sulfonil-2-((s)-2,2,2-trifluoro-1-metil-etoksi)-fenil)-metanona
ATE532516T1 (de) 2007-03-05 2011-11-15 Hoffmann La Roche Verfahren zur synthese von glyt-1-hemmern
AU2008258549B2 (en) 2007-06-08 2013-11-14 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
CA2687754C (en) * 2007-06-08 2015-12-08 Janssen Pharmaceutica N.V. Piperidine, piperazine derivatives for use as dgat inhibitors
WO2008148851A1 (en) * 2007-06-08 2008-12-11 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
JO2972B1 (en) * 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
CA2691450A1 (en) 2007-08-22 2009-02-26 Abbott Gmbh & Co. Kg 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy
EP2271625B1 (de) 2008-04-01 2012-09-12 Abbott GmbH & Co. KG Tetrahydroisochinoline, pharmazeutische zusammensetzungen damit und ihre therapeutische verwendung
WO2009147170A2 (en) 2008-06-05 2009-12-10 Janssen Pharmaceutica Nv Drug combinations comprising a dgat inhibitor and a ppar-agonist
US20160283652A1 (en) 2008-08-29 2016-09-29 Treventis Corporation Methods for identifying inhibitors of amyloid protein aggregation
CN102170882B (zh) * 2008-08-29 2014-04-02 特温蒂斯公司 治疗淀粉状蛋白疾病的组合物和其制药用途
MX2011004350A (es) 2008-11-04 2011-05-23 Hoffmann La Roche Inhibidores radiomarcados del transportador de glicina 1.
CN101759665B (zh) * 2008-12-23 2012-03-28 江苏恩华药业股份有限公司 取代苯基哌嗪芳烷醇衍生物及其在制备镇痛药物中的应用
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
WO2011002067A1 (ja) * 2009-07-02 2011-01-06 武田薬品工業株式会社 複素環化合物およびその用途
US20120035156A1 (en) * 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
CA2844275A1 (en) 2011-08-05 2013-02-14 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
MX2014006004A (es) 2011-11-18 2015-04-16 Abbvie Deutschland Derivados de aminobenzociclohepteno, aminotetralina, aminoindano y fenalcilamina n-sustituidas, composiciones farmaceuticas que los contienen, y su uso en terapia.
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2014163156A1 (ja) * 2013-04-04 2014-10-09 味の素株式会社 脱保護方法
WO2014192865A1 (ja) * 2013-05-30 2014-12-04 大日本住友製薬株式会社 フェニルピペラジン誘導体
KR101472916B1 (ko) 2013-06-27 2014-12-16 한국과학기술연구원 모르폴린 또는 피페라진 화합물, 및 도네페질을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물
SG11201602982YA (en) 2013-10-17 2016-05-30 Abbvie Deutschland Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
AU2014336154A1 (en) 2013-10-17 2016-04-28 AbbVie Deutschland GmbH & Co. KG Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
CN104628679B (zh) * 2013-11-08 2018-02-09 江苏恩华药业股份有限公司 Bitopertin的合成方法及其中间体
WO2015082367A1 (en) * 2013-12-03 2015-06-11 F. Hoffmann-La Roche Ag Pharmaceutical composition
RU2577039C2 (ru) * 2014-02-28 2016-03-10 Закрытое Акционерное Общество "Вертекс" Вещество, обладающее сочетанной антиагрегантной, антикоагулянтной и вазодилаторной активностью, и способ получения n, n'-замещенных пиперазинов
US9708334B2 (en) 2014-04-24 2017-07-18 Dart Neuroscience (Cayman) Ltd. Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine compounds as GlyT1 inhibitors
MA39927B1 (fr) * 2014-04-30 2018-09-28 Hoffmann La Roche Inhibiteurs de glyt1 pour le traitement de troubles hématologiques
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
EP3215500A1 (de) 2014-11-05 2017-09-13 Dart NeuroScience (Cayman) Ltd. Substituierte azetidinylverbindungen als glyt1-inhibitoren
CN105712952B (zh) * 2014-12-22 2021-03-26 上海翰森生物医药科技有限公司 2-取代氧基-5-甲砜基苯基哌嗪酰胺类似物及其制备方法和用途
CN105017098A (zh) * 2015-07-17 2015-11-04 大连奇凯医药科技有限公司 烷氧基类苯磺酰胺及其衍生物的制备工艺
CN106397312B (zh) * 2015-07-31 2020-03-24 广东东阳光药业有限公司 一种制备glyt-1抑制剂的方法
AU2019280689A1 (en) 2018-06-05 2021-01-21 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
JP2023509792A (ja) 2020-01-09 2023-03-09 ディスク・メディシン・インコーポレイテッド グリシン輸送阻害剤を用いて骨髄性プロトポルフィリン症、ｘ連鎖プロトポルフィリン症または先天性赤血球生成性ポルフィリン症を処置する方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5018112A (en) * 1982-10-18 1991-05-21 Conoco Inc. Method for hydrocarbon reservoir identification
IT1176613B (it) * 1984-08-14 1987-08-18 Ravizza Spa Derivati piperazinici farmacologicamente attivi e processo per la loro preparazione
JPH0651625B2 (ja) 1986-12-29 1994-07-06 株式会社大塚製薬工場 高脂質血症治療剤
SK13092000A3 (sk) * 1998-03-06 2001-03-12 Janssen Pharmaceutica N. V. Inhibítory prenosu glycínu, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a ich použitie
GB0021419D0 (en) * 2000-08-31 2000-10-18 Oxford Glycosciences Uk Ltd Compounds
DE10112040A1 (de) 2001-03-14 2002-10-02 Aventis Pharma Gmbh Verbessertes Verfahren zur Herstellung von Sulfonylcarboxamidderivaten
CN1620294A (zh) * 2001-12-20 2005-05-25 Osi药物公司 嘧啶a2b选择性拮抗剂化合物,它们的合成及用途
ES2297458T3 (es) 2003-08-11 2008-05-01 F. Hoffmann-La Roche Ag Piperazina con grupo fenilo or-sustituido y su empleo como inhibidores de glyti.

Also Published As

Publication number Publication date
CR8193A (es) 2006-10-06
TW200524883A (en) 2005-08-01
CN1867554B (zh) 2011-07-06
IL173274A (en) 2012-06-28
ES2297458T3 (es) 2008-05-01
EP1656361A1 (de) 2006-05-17
HK1098147A1 (en) 2007-07-13
AR045360A1 (es) 2005-10-26
NO20060541L (no) 2006-03-08
IL173274A0 (en) 2006-06-11
BRPI0413497A (pt) 2006-10-17
CA2534675A1 (en) 2005-02-17
PT1656361E (pt) 2008-03-05
US20080119486A1 (en) 2008-05-22
MEP27708A (en) 2010-06-10
NO332263B1 (no) 2012-08-13
TNSN06042A1 (en) 2007-10-03
ATE382611T1 (de) 2008-01-15
ZA200601146B (en) 2007-05-30
MA27995A1 (fr) 2006-07-03
US7319099B2 (en) 2008-01-15
AU2004263306A1 (en) 2005-02-17
MXPA06001665A (es) 2006-04-28
CN1867554A (zh) 2006-11-22
CO5650253A2 (es) 2006-06-30
UA85194C2 (ru) 2009-01-12
TWI289556B (en) 2007-11-11
KR20060037434A (ko) 2006-05-03
EG26404A (en) 2013-10-21
PL1656361T3 (pl) 2008-06-30
RS20060076A (en) 2008-08-07
NZ544820A (en) 2009-02-28
EA200600336A1 (ru) 2006-08-25
ME00116B (me) 2010-10-10
HRP20080137T3 (en) 2008-06-30
JP2007501820A (ja) 2007-02-01
CY1108616T1 (el) 2014-04-09
AU2004263306A2 (en) 2005-02-17
DE602004011076T2 (de) 2009-01-02
JP4252598B2 (ja) 2009-04-08
RS53252B (en) 2014-08-29
US7605163B2 (en) 2009-10-20
WO2005014563A1 (en) 2005-02-17
BRPI0413497B8 (pt) 2021-05-25
CA2534675C (en) 2013-07-23
EP1656361B1 (de) 2008-01-02
MY145356A (en) 2012-01-31
EA009986B1 (ru) 2008-04-28
KR100774622B1 (ko) 2007-11-08
SI1656361T1 (sl) 2008-04-30
ECSP066358A (es) 2006-08-30
BRPI0413497B1 (pt) 2017-12-19
US20050209241A1 (en) 2005-09-22
DK1656361T3 (da) 2008-05-05
AU2004263306B2 (en) 2010-04-22

Similar Documents

Publication Publication Date Title
DE602004011076D1 (de) Piperazin mit or-substituierter phenylgruppe und deren verwendung als glyt1-inhibitoren
DE602004021037D1 (de) Phosphororganische indazolderivate und deren verwendung als proteinkinaseinhibitoren
ATE472546T1 (de) 5-heteroarylthiazole und deren verwendung als pi3k-inhibitoren
DE60328087D1 (de) Aryl substituierte pyrimidine und deren verwendung
ATE463482T1 (de) Chinolinderivate und deren verwendung als mycobakterielle inhibitoren
DE60308387D1 (de) Pyrazolenthaltende zusammensetzungen und ihre verwendung als gsk-3 inhibitoren
ATE426597T1 (de) Benzamidderivate und deren verwendung als glucokinaseaktivierende mittel
IS7710A (is) Heterósýklísk setin píperasín til notkunar við meðferð á geðklofa
DE602005003186D1 (de) Fluorkopolymer und dessen Verwendung
ATE437870T1 (de) Prolinderivate und deren verwendung als dipeptidylpeptidase-iv-inhibitoren
ATE511507T1 (de) Piperidinylcarbonylpyrrolidine und deren verwendung als melanocortinagonisten
ATE444068T1 (de) Chinolinderivate und ihre verwendung als mycobakterielle inhibitoren
ATE424383T1 (de) Cyclische amine mit benzamidsubstituent als bace- 1-inhibitoren
ATE428710T1 (de) Substituierte phenylaminothiazole und ihre verwendung
ATE517098T1 (de) Acylaminothiazolderivate und deren verwendung als beta-amyloid-inhibitoren
DE602005011593D1 (de) Substituierte diazaspiroä5.5üundecanderivate und deren verwendung als neurokininantagonisten
DE602005007002D1 (de) Substituierte 4-alkyl- und 4-alkanoylpiperidinderivate und deren verwendung als neurokininantagonisten
DE602005022060D1 (de) Diaminoalkohole und deren verwendung als renininhibitoren
ATE500242T1 (de) Substituierte 1-piperidin-4-yl-pyrrolidin-3-yl- piperazinderivate und deren verwendung als neurokinin antagonisten
ATE423117T1 (de) Heterocyclische 7-aminoalkylidenylchinolone und - naphthyridone
DE60219068D1 (de) Substituierte 2-amino-zykloalkankarboxamide und ihre verwendung als zysteinprotease-inhibitoren
DE602004028700D1 (de) Kosmetische Zusammensetzungen und deren Verwendung
DE60318733D1 (de) Substituierte benzoxazinones und ihre verwendung
ATE555097T1 (de) 4-cycloalkyl-substituierte tetrahydrochinolinderivate und deren verwendung als medikamente
DE602005022920D1 (de) Verbesserungen bei der verwendung von mehrfachkommunikationssystemen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition